Skip to content
Screener

ImmunityBio, Inc. IBRX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$16.99M-7.9%
UroGen Pharma logo
UroGen PharmaURGN
$3.04M+150%
CG Oncology logo
CG OncologyCGON
$5.82M+485%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$46M-11.8%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$9.85M-24.9%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.76B+245%
Enterprise value$8B+230%
P/S55×+15.3×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Years Ending December 31:Operating LeasesFinance LeasesTotal
202811,3497911,428
202910,2217910,300
20307,837347,871
20311,5231,523
Thereafter453453
Total future minimum lease payments51,26933051,599
Less: Interest10,4966410,560
Present value of lease liabilities$40,773$266$41,039

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s operating lease liabilities (total)?
ImmunityBio, Inc. (IBRX) reported operating lease liabilities (total) of $40.77M in Q1 2026.
How has ImmunityBio, Inc.'s operating lease liabilities (total) changed year-over-year?
ImmunityBio, Inc.'s operating lease liabilities (total) increased by 0.5% year-over-year, from $40.56M to $40.77M.
What is the long-term trend for ImmunityBio, Inc.'s operating lease liabilities (total)?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s operating lease liabilities (total) has grown at a 21.8% compound annual growth rate (CAGR), from $15.31M to $40.98M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about ImmunityBio, Inc.'s operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude